Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 7/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11015703 | 0.77 | CYP3A4 (0.40) | CYP3A4TSHR | |
| SCHEMBL1968808 | 0.77 | ADRB1 (0.43) | SYK | |
| SCHEMBL27573365 | 0.76 | ADRB1 (0.42) | SYK | |
| SCHEMBL279200 | 0.74 | SYK (0.39) | SYKLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL803084 | 0.74 | SYK (0.39) | SYKLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL22903513 | 0.74 | SYK (0.36) | SYKLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL28872199 | 0.73 | SYK (0.38) | SYKLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL21719185 | 0.73 | SYK (0.38) | SYKLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL17586505 | 0.73 | SYK (0.38) | SYKLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL179501 | 0.73 | NUDT1 (0.48) | SYKHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | UNIVERSITY OF OULU (FI) | 2023-10-12 | — | — | US | disclosed |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | UNIVERSITY OF OULU (FI) | 2023-10-12 | — | — | US | disclosed |
| WO-2023109912-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2023-06-22 | — | — | WO | disclosed |
| US-20210230123-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2021-07-29 | — | — | US | disclosed |
| US-20180134667-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2018-05-17 | — | — | US | disclosed |
| US-8921555-B2 | Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones | MERCK SHARP & DOHME CORP. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8895580-B2 | Quinolinone-pyrazolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2488514-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | Proximagen Limited (GB) | 2012-08-22 | — | — | EP | disclosed |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-08-02 | — | — | US | disclosed |
| US-20120095001-A1 | SUBSTITUTED-1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES | MERCK SHARP & DOHME CORP. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | ARRAY BIOPHARMA, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | ARRAY BIOPHARMA, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | GRM1, GRIN1, GRM2 | SYK 2251/4885LMNA 4832/4885SMN1; SMN2 4205/4885 |
| US-20120095001-A1 | SUBSTITUTED-1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES | HIF1AN, HIF1A, EGLN2 | SYK 4204/4885LMNA 4005/4885SMN1; SMN2 4257/4885 |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | CBR3, GBA3, TECR | SYK 2398/4885LMNA 1966/4885SMN1; SMN2 3972/4885 |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | GRIK1, GRIK2, GRIK4 | SYK 1661/4885LMNA 4024/4885SMN1; SMN2 3201/4885 |
| US-20210230123-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | SYK 4445/4885LMNA 2315/4885SMN1; SMN2 1791/4885 |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRNA5 | SYK 1520/4885LMNA 4018/4885SMN1; SMN2 1644/4885 |
| US-20180134667-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | SYK 4445/4885LMNA 2315/4885SMN1; SMN2 1791/4885 |
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | HTR7, UGT2B7, HK1 | SYK 3695/4885LMNA 1369/4885SMN1; SMN2 1741/4885 |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | LTB4R, LTB4R2, CYSLTR1 | SYK 3060/4885LMNA 1806/4885SMN1; SMN2 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.